passage in vivo by injecting 1-5 x 106 cells per mouse, i.p., in BALB/c mice. The SSM (lot No. 123, C-1) (Kobatake et al., 1981) was kindly supplied by the Zeria Pharmaceutical Co., Ltd., Tokyo, Japan.
SSM (5-500pgkg-1, i.p.) or saline (0.5ml, i.p.) was administered one day before and one day after tumour inoculation, and was subsequently continued every other day for a total of 10 treatments. Two kinds of immunocompromised animals were used in this study: (i) Mice treated with anti-mouse IFNy antiserum which was prepared in rabbits immunized with staphylococcal enterotoxin A (SEA)-induced IFNy. This material has been shown to preferentially inactivate the antiviral activity of IFNy in vitro while not reacting with IFNoa or IFN,B (Osborne et al., 1980) . Since 5mg kg-' of SSM administered i.v. to mice has been reported to result in peak IFNy titers of 320Uml-1 in the circulation (Hayashi et al., 1981) , a dose of this antiserum capable of neutralizing 2,500 U kg-1 of IFN was given s.c. to mice immediately after administering SSM. (ii)
Congenitally athymic nude (nu/nu) mice homozygous for the recessive gene (nu), which were severely limited in thymus-derived lymphocytes. These animals are deficient in Thy 1 + T lymphocytes (Pantelouris, 1968) which have been shown to produce IFNy (Sonnenfeld et al., 1979) . As a positive control, normal BALB/c mice were stimulated with SSM to induce IFN. Although haired littermates of the nude mice are heterozygous at the nu gene locus (nu/ +), their T cell functions have been reported to be intact (Pantelouris, 1971) . These nu/ + mice also served as positive controls. After inoculation of the tumour cells, mice were observed daily until day 50, and the percent survival was calculated from the number of mice which survived more than 50 days after tumour inoculation. For the determination of circulating IFN, blood samples were obtained from various mice at appropriate intervals after the injection of SSM. The blood samples were kept at 4°C overnight, then centrifuged at 1,250g for 30 min, and obtained serum specimens were assayed for IFN on L-Galveston cells in a microplaque reduction assay as described previously (Suzuki & Pollard, 1982) . To determine the dose response effect of SSM on IFN induction in various mice, sera were harvested 20 h after various doses of SSM administration. IFN levels were expressed as international Uml-1 as compared to the standard murine IFN (G-002-904-511) . One U of the experimental IFN samples was equivalent to 1.2U of the international standard.
As shown in Figure 1 , although normal and nu/ + mice treated i.p. with 2.5mg kg-' of SSM had IFN in the circulation which peaked 20h after SSM administration, normal mice treated with anti-mouse IFNy antiserum and nu/nu mice stimulated with the same concentration of SSM had no detectable serum IFN activity at any of the time intervals examined. The impaired IFNy responsiveness in immunocompromised mice treated with SSM was also observed following the administration of various concentrations of SSM. Sera were harvested 20h after SSM injection and assayed. As shown in Figure 2 heterozygous littermates of nude mice and two kinds of immunocompromised mice, the antitumour activity of SSM in these groups of mice was investigated. As shown in Table Ta , significant antitumour activity was olterved in normal mice bearing Ehrlich and RL31 ascites tumours when they were treated with both 500 and 50pugkg-' of SSM. However, when tumour-bearing normal mice were treated i.p. with 5upgkg-1 of SSM or 0.5ml of saline, all died. In addition, when nu/ + mice bearing tumours received 500pgkg-1 of SSM, the antitumour effect was equivalent to that observed in normal mice (Table Ib) . The antitumour activity of SSM was, therefore, detectable in this experimental tumour model and the following experiments were performed utilizing the two groups of immunocompromised mice. As shown in Table Ic , a significant protective effect was noted in tumourbearing mice treated with anti-mouse IFNy antiserum and 500 or 50pgkg-1 of SSM as compared to those treated with saline. In T cell deficient (nu/nu) mice, however, no protective effect of SSM was observed possibly due to a deficit in supressor/cytotoxic Ly-2,3 + T cells, which also produce IFNy (Sonnenfeld et al., 1979 (Sikora et al., 1983) , the antitumour activity associated with IFN inducers (or immunopotentiators) appears to be dependent upon the induction of IFN. The present study suggests that the antitumour activity of SSM may not be related to the induction of circulating IFN. However, T cells appear to be required since tumour-bearing T cell deficient mice (nu/nu mice) did not reveal a tumour inhibitory effect after SSM administration. SSM had no direct cytoxicity against cancer cells in vitro (Kimoto et al., 1982) , and cells considered to be possible effectors in antitumour activity including NK cells, CTL, and activated MO have been reported to be stimulated by SSM. These observations suggest that the antitumour effect of SSM are mediated by more than one mechanism. The data described here indicate that circulating IFNy induction by SSM may not be related to its suppression of tumours inoculated in mice.
